$CDNA
CareDx Inc Stock $cdna

$cdna Overview Financials Valuation SEC Filings Company Website

2018 Form 10-K Financial Statement

#000156459019006533 Filed on March 06, 2019

Income Statement

Concept	2018	2017 Q4	2017 Q3
Revenue	$76.57M	$12.50M	$12.19M
YoY Change	15213.8%	15.14%	-2.28%
Cost Of Revenue	$32.99M	$5.590M	$5.210M
YoY Change	54.35%	-13.73%	100.08%
Gross Profit	$43.58M	$6.910M	$6.980M
YoY Change	61.7%	57.76%	-29.29%
Gross Profit Margin	56.92%	55.27%	57.26%
Selling, General & Admin	$44.65M	$7.300M	$7.290M
YoY Change	35.7%	2.82%	-15.53%
% of Gross Profit	102.44%	105.64%	104.44%
Research & Development	$14.51M	$3.030M	$2.960M
YoY Change	17.16%	-3.81%	1.02%
% of Gross Profit	33.3%	43.85%	42.41%
Depreciation & Amortization	$1.200M	$1.020M	$920.0K
YoY Change	0.0%	41.67%	-16.36%
% of Gross Profit	2.75%	14.76%	13.18%
Operating Expenses	$92.15M	$11.20M	$10.85M
YoY Change	95.03%	9.59%	-5.24%
Operating Profit	-$15.58M	-$4.290M	-$3.870M
YoY Change	-23.24%	-26.54%	145.09%
Interest Expense	-$3.701M	-$27.92M	-$10.28M
YoY Change	-36.88%	-2837.25%	-1909.86%
% of Operating Profit
Other Income/Expense, Net	-$32.64M	-$300.0K	-$320.0K
YoY Change	-11.73%	-121.28%	146.15%
Pretax Income	-$48.22M	-$32.50M	-$14.47M
YoY Change	-15.81%	97.81%	240.63%
Income Tax	-$1.434M	-$73.37M	-$180.0K
% Of Pretax Income
Net Earnings	-$46.76M	-$31.67M	-$14.27M
YoY Change	-15.71%	104.55%	279.06%
Net Earnings / Revenue	-61.06%	-253.31%	-117.04%
Basic Earnings Per Share	-$1.31	-$1.13	-$0.63
Diluted Earnings Per Share	-$1.31	-$1.13	-$0.63
COMMON SHARES
Basic Shares Outstanding	35.64M shares	27.98M	22.53M
Diluted Shares Outstanding	35.64M shares	27.98M	22.53M

Balance Sheet

Concept	2018	2017 Q4	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$64.60M	$16.90M	$6.000M
YoY Change	282.25%	-2.31%	-73.09%
Cash & Equivalents	$64.60M	$16.90M	$15.53M
Short-Term Investments
Other Short-Term Assets	$1.800M	$1.400M	$1.500M
YoY Change	28.57%	16.67%	87.5%
Inventory	$4.900M	$5.529M	$6.200M
Prepaid Expenses
Receivables	$9.800M	$2.991M	$3.300M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$81.10M	$26.77M	$16.90M
YoY Change	202.61%	0.25%	-51.88%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.100M	$2.075M	$2.300M
YoY Change	95.24%	-28.45%	-30.41%
Goodwill		$12.01M
YoY Change		-13.25%
Intangibles		$33.14M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$200.0K	$9.600M	$9.600M
YoY Change	-97.92%	4700.0%	31900.0%
Total Long-Term Assets	$49.60M	$56.80M	$58.19M
YoY Change	-12.68%	13.6%	-13.1%
TOTAL ASSETS
Total Short-Term Assets	$81.10M	$26.77M	$16.90M
Total Long-Term Assets	$49.60M	$56.80M	$58.19M
Total Assets	$130.7M	$83.57M	$75.09M
YoY Change	56.34%	8.95%	-26.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.700M	$3.391M	$3.400M
YoY Change	38.24%	9.39%	-1.85%
Accrued Expenses	$11.20M	$8.700M	$8.600M
YoY Change	28.74%	-7.45%	-29.51%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$200.0K	$15.72M	$15.00M
YoY Change	-98.73%	-31.19%	-16.21%
Total Short-Term Liabilities	$19.50M	$42.91M	$31.00M
YoY Change	-54.55%	5.08%	-21.73%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$18.34M	$21.17M
YoY Change	-100.0%	1570.13%	149.22%
Other Long-Term Liabilities	$12.30M	$1.315M	$1.313M
YoY Change	-47.21%	7.61%	-87.25%
Total Long-Term Liabilities	$12.30M	$19.65M	$22.49M
YoY Change	-70.43%	747.11%	164.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$19.50M	$42.91M	$31.00M
Total Long-Term Liabilities	$12.30M	$19.65M	$22.49M
Total Liabilities	$34.80M	$89.52M	$75.27M
YoY Change	-61.2%	57.14%	56.48%
SHAREHOLDERS EQUITY
Retained Earnings		-$268.0M	-$236.4M
YoY Change		26.1%
Common Stock		$264.2M	$238.2M
YoY Change		12.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$95.90M	-$6.134M	-$311.0K
YoY Change
Total Liabilities & Shareholders Equity	$130.7M	$83.57M	$75.09M
YoY Change	56.34%	8.91%	-26.45%

Cashflow Statement

Concept	2018	2017 Q4	2017 Q3
OPERATING ACTIVITIES
Net Income	-$46.76M	-$31.67M	-$14.27M
YoY Change	-15.71%	104.55%	279.06%
Depreciation, Depletion And Amortization	$1.200M	$1.020M	$920.0K
YoY Change	0.0%	41.67%	-16.36%
Cash From Operating Activities	-$4.007M	-$2.150M	-$2.220M
YoY Change	-71.99%	-29.74%	85.0%
INVESTING ACTIVITIES
Capital Expenditures	$2.035M	-$90.00K	-$10.00K
YoY Change	994.09%	-212.5%	-97.14%
Acquisitions
YoY Change
Other Investing Activities	-$690.0K	-$4.950M	-$970.0K
YoY Change	-88.34%
Cash From Investing Activities	-$7.929M	-$5.040M	-$980.0K
YoY Change	29.88%	-7300.0%	180.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$50.27M	17.92M	110.0K
YoY Change	71.1%	-941.31%	-98.35%
NET CHANGE
Cash From Operating Activities	-$4.007M	-2.150M	-2.220M
Cash From Investing Activities	-$7.929M	-5.040M	-980.0K
Cash From Financing Activities	$50.27M	17.92M	110.0K
Net Change In Cash	$38.33M	10.73M	-3.090M
YoY Change	322.51%	-309.57%	-160.23%
FREE CASH FLOW
Cash From Operating Activities	-$4.007M	-$2.150M	-$2.220M
Capital Expenditures	$2.035M	-$90.00K	-$10.00K
Free Cash Flow	-$6.042M	-$2.060M	-$2.210M
YoY Change	-58.31%	-34.39%	160.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2018	dei	Entity Small Business EntitySmallBusiness	true
CY2018	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2019Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41728442
CY2018Q2	dei	Entity Public Float EntityPublicFloat	321787874
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64616000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	16895000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9760000
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2991000
CY2018Q4	us-gaap	Inventory Net InventoryNet	4943000
CY2017Q4	us-gaap	Inventory Net InventoryNet	5529000
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1795000
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1352000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	81114000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	26767000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4134000
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2075000
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	33252000
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	33139000
CY2018Q4	us-gaap	Goodwill Goodwill	12005000
CY2017Q4	us-gaap	Goodwill Goodwill	12005000
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	192000
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	9579000
CY2017Q4	us-gaap	Assets Assets	83565000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	42906000
CY2017	cdna	Extinguishment Of Debt And Conversion Of Debt To Equity Expenses ExtinguishmentOfDebtAndConversionOfDebtToEquityExpenses	459000
CY2016	cdna	Extinguishment Of Debt And Conversion Of Debt To Equity Expenses ExtinguishmentOfDebtAndConversionOfDebtToEquityExpenses	0
CY2018	cdna	Extinguishment Of Debt And Conversion Of Debt To Equity Expenses ExtinguishmentOfDebtAndConversionOfDebtToEquityExpenses	5780000
CY2018	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-22978000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	76569000
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	48324000
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3391000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-178000
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1031000
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1920000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-57269000
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1606000
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2018Q4	cdna	Business Acquisition Deferred Payment Consideration With Interest Accretion Current Portion BusinessAcquisitionDeferredPaymentConsiderationWithInterestAccretionCurrentPortion	190000
CY2017Q4	cdna	Business Acquisition Deferred Payment Consideration With Interest Accretion Current Portion BusinessAcquisitionDeferredPaymentConsiderationWithInterestAccretionCurrentPortion	407000
CY2018Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	14600000
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	15721000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-6134000
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-5954000
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	913000
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	730000
CY2017Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	4933000
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	18338000
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	1672000
CY2017Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	18712000
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1315000
CY2017Q4	us-gaap	Liabilities Liabilities	89519000
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	29000
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	412010000
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	264204000
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2345000
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-268022000
CY2017Q4	us-gaap	Minority Interest MinorityInterest	180000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	83565000
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5013000
CY2017Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	3735000
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2016	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40631000
CY2017	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-29622000
CY2016	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-250000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-48215000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1434000
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1709000
CY2018	us-gaap	Profit Loss ProfitLoss	-46781000
CY2017	us-gaap	Profit Loss ProfitLoss	-55560000
CY2016	us-gaap	Profit Loss ProfitLoss	-39756000
CY2018	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-25000
CY2017	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-91000
CY2016	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-287000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-46756000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-55469000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-39469000
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.31
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.38
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.39
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.31
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.38
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.39
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35638956
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23332503
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	16496911
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35638956
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	23332503
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	16496911
CY2018	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1933000
CY2017	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	1306000
CY2016	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3727000
CY2018	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-48714000
CY2017	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-54254000
CY2016	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-43483000
CY2018	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-25000
CY2017	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-99000
CY2016	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-355000
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-48689000
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28825019
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28825019
CY2016	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	304000
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	19000
CY2016	cdna	Issuance Of Common Stock Initial Public Offering IssuanceOfCommonStockInitialPublicOffering	7925000
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	304000
CY2015Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	29494000
CY2016	cdna	Stock Issued During Period Value Business Acquisitions StockIssuedDuringPeriodValueBusinessAcquisitions	7205000
CY2016	cdna	Stock Issued During Period Value Preferred Stock Issued Through Private Placement And Subsequent Financing StockIssuedDuringPeriodValuePreferredStockIssuedThroughPrivatePlacementAndSubsequentFinancing	13064000
CY2016	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5000
CY2016	cdna	Stock Issued During Period Value Stock Issued Through Private Placement And Subsequent Financing StockIssuedDuringPeriodValueStockIssuedThroughPrivatePlacementAndSubsequentFinancing	2596000
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-54155000
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-43128000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1694000
CY2016	cdna	Noncontrolling Interest Increase Decrease From Business Combination NoncontrollingInterestIncreaseDecreaseFromBusinessCombination	634000
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19761000
CY2017	cdna	Issuance Of Common Stock Initial Public Offering IssuanceOfCommonStockInitialPublicOffering	18329000
CY2017	cdna	Stock Issued During Period Value Business Acquisitions StockIssuedDuringPeriodValueBusinessAcquisitions	1146000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	1676000
CY2017	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	94000
CY2017	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	245000
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	262000
CY2017	cdna	Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue	989000
CY2017	cdna	Issuance Of Common Stock Upon Exercise Of Warrants Value IssuanceOfCommonStockUponExerciseOfWarrantsValue	4306000
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1492000
CY2018	cdna	Adjustments To Additional Paid In Capital Reclassification Of Warrants From Liability To Equity AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantsFromLiabilityToEquity	6550000
CY2018	cdna	Issuance Of Common Stock Initial Public Offering IssuanceOfCommonStockInitialPublicOffering	52549000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	38852000
CY2018	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	287000
CY2018	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-698000
CY2018	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	273000
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1480000
CY2018	cdna	Issuance Of Common Stock For Cash Upon Exercise Of Warrants Value IssuanceOfCommonStockForCashUponExerciseOfWarrantsValue	38712000
CY2018	cdna	Noncontrolling Interest Increase Decrease From Business Combination NoncontrollingInterestIncreaseDecreaseFromBusinessCombination	-692000
CY2018	cdna	Stock Issued During Period Value Business Acquisitions StockIssuedDuringPeriodValueBusinessAcquisitions	2689000
CY2018	cdna	Issuance Of Warrants In Connection With Perceptive Debt IssuanceOfWarrantsInConnectionWithPerceptiveDebt	784000
CY2018	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	3800000
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4215000
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3759000
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2920000
CY2018	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	234000
CY2017	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	418000
CY2016	us-gaap	Cost Of Goods And Services Sold Depreciation CostOfGoodsAndServicesSoldDepreciation	4175000
CY2018	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-10000
CY2016	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	7138000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	1744000
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	1998000
CY2018	cdna	Amortization Of Deferred Revenue AmortizationOfDeferredRevenue	0
CY2017	cdna	Amortization Of Deferred Revenue AmortizationOfDeferredRevenue	32000
CY2016	cdna	Amortization Of Deferred Revenue AmortizationOfDeferredRevenue	45000
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2232000
CY2017	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3452000
CY2016	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	-101000
CY2018	cdna	Loss On Conversion Of Debt To Equity LossOnConversionOfDebtToEquity	5831000
CY2017	cdna	Loss On Conversion Of Debt To Equity LossOnConversionOfDebtToEquity	274000
CY2016	cdna	Loss On Conversion Of Debt To Equity LossOnConversionOfDebtToEquity	0
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3967000
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	109000
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1047000
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-363000
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1025000
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-492000
CY2018	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	502000
CY2017	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	84000
CY2016	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-999000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-168000
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	292000
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-620000
CY2018	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	4291000
CY2017	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	1065000
CY2016	us-gaap	Increase Decrease In Accrued Salaries IncreaseDecreaseInAccruedSalaries	977000
CY2018	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	0
CY2017	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	-263000
CY2016	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	21000
CY2018	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	758000
CY2017	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-970000
CY2016	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-105000
CY2018	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-39000
CY2017	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0
CY2016	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0
CY2018	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1607000
CY2017	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	2088000
CY2016	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	1340000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4007000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14307000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16523000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2035000
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	186000
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	549000
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5202000
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7929000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-6105000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21121000
CY2018	cdna	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	52910000
CY2017	cdna	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	18328000
CY2016	cdna	Proceeds From Issuance Of Common Stock Net Of Issuance Costs ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts	7926000
CY2018	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	14282000
CY2017	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	24002000
CY2016	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0
CY2018	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	28089000
CY2017	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	14359000
CY2016	us-gaap	Repayments Of Long Term Debt And Capital Securities RepaymentsOfLongTermDebtAndCapitalSecurities	3944000
CY2018	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-677000
CY2017	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	0
CY2016	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	0
CY2018	cdna	Proceeds From Private Placement And Subsequent Financing Net Of Issuance Costs ProceedsFromPrivatePlacementAndSubsequentFinancingNetOfIssuanceCosts	0
CY2017	cdna	Proceeds From Private Placement And Subsequent Financing Net Of Issuance Costs ProceedsFromPrivatePlacementAndSubsequentFinancingNetOfIssuanceCosts	0
CY2016	cdna	Proceeds From Private Placement And Subsequent Financing Net Of Issuance Costs ProceedsFromPrivatePlacementAndSubsequentFinancingNetOfIssuanceCosts	20622000
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	10998000
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	989000
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1480000
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	262000
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	19000
CY2018	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	287000
CY2017	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	94000
CY2016	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	304000
CY2018	cdna	Taxes Paid Related To Net Share Settlement Of Restricted Stock Units TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits	698000
CY2017	cdna	Taxes Paid Related To Net Share Settlement Of Restricted Stock Units TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits	0
CY2016	cdna	Taxes Paid Related To Net Share Settlement Of Restricted Stock Units TaxesPaidRelatedToNetShareSettlementOfRestrictedStockUnits	0
CY2018	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts	0
CY2017	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts	63000
CY2016	us-gaap	Proceeds From Repayments Of Bank Overdrafts ProceedsFromRepaymentsOfBankOverdrafts	0
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	50268000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	29379000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	24927000
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2000
CY2017	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	106000
CY2016	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	83000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	26474000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17401000
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30035000
CY2016	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12634000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	38334000
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9073000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	64808000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	1774000
CY2017	us-gaap	Interest Paid Net InterestPaidNet	3270000
CY2016	us-gaap	Interest Paid Net InterestPaidNet	867000
CY2018	cdna	Shares Issued In Lieu Of Cash Payment SharesIssuedInLieuOfCashPayment	0
CY2017	cdna	Shares Issued In Lieu Of Cash Payment SharesIssuedInLieuOfCashPayment	1145000
CY2016	cdna	Shares Issued In Lieu Of Cash Payment SharesIssuedInLieuOfCashPayment	0
CY2018	cdna	Business Acquisition Deferred Payment Consideration BusinessAcquisitionDeferredPaymentConsideration	0
CY2017	cdna	Business Acquisition Deferred Payment Consideration BusinessAcquisitionDeferredPaymentConsideration	0
CY2016	cdna	Business Acquisition Deferred Payment Consideration BusinessAcquisitionDeferredPaymentConsideration	5700000
CY2018	cdna	Accrued Interest Capitalized To Debt Principal AccruedInterestCapitalizedToDebtPrincipal	0
CY2017	cdna	Accrued Interest Capitalized To Debt Principal AccruedInterestCapitalizedToDebtPrincipal	984000
CY2016	cdna	Accrued Interest Capitalized To Debt Principal AccruedInterestCapitalizedToDebtPrincipal	0
CY2018	cdna	Common Stock Issued For Acquisition CommonStockIssuedForAcquisition	0
CY2017	cdna	Common Stock Issued For Acquisition CommonStockIssuedForAcquisition	0
CY2016	cdna	Common Stock Issued For Acquisition CommonStockIssuedForAcquisition	7205000
CY2018	cdna	Debt Assumed As Part Of Acquisition DebtAssumedAsPartOfAcquisition	0
CY2017	cdna	Debt Assumed As Part Of Acquisition DebtAssumedAsPartOfAcquisition	0
CY2016	cdna	Debt Assumed As Part Of Acquisition DebtAssumedAsPartOfAcquisition	13421000
CY2018	cdna	Conversion Of Convertible Preferred Stock To Common Stock At Private Placement And Subsequent Financing ConversionOfConvertiblePreferredStockToCommonStockAtPrivatePlacementAndSubsequentFinancing	0
CY2017	cdna	Conversion Of Convertible Preferred Stock To Common Stock At Private Placement And Subsequent Financing ConversionOfConvertiblePreferredStockToCommonStockAtPrivatePlacementAndSubsequentFinancing	0
CY2016	cdna	Conversion Of Convertible Preferred Stock To Common Stock At Private Placement And Subsequent Financing ConversionOfConvertiblePreferredStockToCommonStockAtPrivatePlacementAndSubsequentFinancing	13064000
CY2018	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	38852000
CY2017	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0
CY2016	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0
CY2018	cdna	Offering Costs OfferingCosts	361000
CY2017	cdna	Offering Costs OfferingCosts	0
CY2016	cdna	Offering Costs OfferingCosts	0
CY2018	cdna	Employee Stock Purchase Plan Shares EmployeeStockPurchasePlanShares	341000
CY2017	cdna	Employee Stock Purchase Plan Shares EmployeeStockPurchasePlanShares	0
CY2016	cdna	Employee Stock Purchase Plan Shares EmployeeStockPurchasePlanShares	0
CY2018	cdna	Debt Conversion Converted Instrument Common Stock Warrants Issued DebtConversionConvertedInstrumentCommonStockWarrantsIssued	784000
CY2017	cdna	Debt Conversion Converted Instrument Common Stock Warrants Issued DebtConversionConvertedInstrumentCommonStockWarrantsIssued	0
CY2016	cdna	Debt Conversion Converted Instrument Common Stock Warrants Issued DebtConversionConvertedInstrumentCommonStockWarrantsIssued	0
CY2018	cdna	Common Stock Shares Issued For Contingent Consideration CommonStockSharesIssuedForContingentConsideration	2689000
CY2017	cdna	Common Stock Shares Issued For Contingent Consideration CommonStockSharesIssuedForContingentConsideration	0
CY2016	cdna	Common Stock Shares Issued For Contingent Consideration CommonStockSharesIssuedForContingentConsideration	0
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17258000
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	143000
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Use of Estimates </font></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in the consolidated financial statements and accompanying notes.  On an ongoing basis, management evaluates its estimates, including those related to transaction price estimates used for testing revenue; accrued expenses for clinical studies; inventory valuation; the fair value of issued common stock warrants and embedded derivatives; the fair value of assets and liabilities acquired in a business combination or an assets acquisition (including identifiable intangible assets acquired); the fair value of contingent consideration recorded in connection with a business combination; the grant date fair value assumptions used to estimate stock-based compensation expense; income taxes; impairment of long-lived assets and indefinite-lived assets (including goodwill); and legal contingencies. Actual results could differ from those estimates. </p>
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Concentrations of Credit Risk and Other Risks and Uncertainties </font></p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and accounts receivable.  The Company’s policy is to invest its cash and cash equivalents in money market funds, obligations of U.S. government agencies and government-sponsored entities, commercial paper and various bank deposit accounts.  These financial instruments are held in Company accounts at eight financial institutions.  The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing.  The Company is exposed to credit risk in the event of default by the financial institutions to the extent of amounts recorded on the balance sheets that may be in excess of insured limits. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also subject to credit risk from its accounts receivable, which are derived from revenue earned from AlloMap and AlloSure tests provided for patients located in the U.S. and billed to various third-party payers, and from sales of products to distributors, strategic partners and transplant laboratories in Europe, the Middle East, Africa, the U.S., Latin America and other geographic regions.  The Company has not experienced any significant credit losses and does not require collateral on receivables.  For the years ended December 31, 2018, 2017 and 2016, approximately 48%, 27% and 44%, respectively, of total revenue was billed to Medicare.  No other payers represented more than 10% of total revenue for the years ended December 31, 2018, 2017 and 2016. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2018 and 2017, approximately 27% and 16%, respectively, of accounts receivable was due from Medicare.  No other payer represented more than 10% of accounts receivable at either December 31, 2018 or 2017. </p>
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	402000
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	30802000
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-55469000
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-39469000
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	34984000
CY2018	cdna	Revenue From Contract With Customer Milestone Method RevenueFromContractWithCustomerMilestoneMethod	0
CY2017	cdna	Revenue From Contract With Customer Milestone Method RevenueFromContractWithCustomerMilestoneMethod	0
CY2016	cdna	Revenue From Contract With Customer Milestone Method RevenueFromContractWithCustomerMilestoneMethod	0
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-46756000
CY2018	cdna	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Exercise Of Warrants FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisExerciseOfWarrants	27714000
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	12268000
CY2018	cdna	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification To Equity FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity	-6550000
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	245000
CY2018	cdna	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Issuances Of Common Stock FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisIssuancesOfCommonStock	-2689000
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	23995000
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	10003000
CY2018	cdna	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
CY2017	cdna	Fair Value Measurements Inter Transfers Between Levels FairValueMeasurementsInterTransfersBetweenLevels	0
CY2018	us-gaap	Additional Cash And Cash Equivalent Related Text AdditionalCashAndCashEquivalentRelatedText	Cash equivalents consist of short-term, highly liquid investments with original maturities of three months or less from the date of purchase.
CY2018Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	200000
CY2018	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4125710
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12411471
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5551325
CY2016Q2	cdna	Preferred Stock Issued Shares Private Placement PreferredStockIssuedSharesPrivatePlacement	4630145
CY2016Q2	cdna	Preferred Stock Issued Shares Subsequent Financing PreferredStockIssuedSharesSubsequentFinancing	4630145
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	5700000
CY2017	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues	3190000
CY2017	cdna	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Exercise Of Warrants FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisExerciseOfWarrants	4306000
CY2016Q4	us-gaap	Goodwill Goodwill	13839000
CY2017	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	85000
CY2017	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	39000
CY2018	us-gaap	New Date Of Annual Goodwill Impairment Test NewDateOfAnnualGoodwillImpairmentTest	On January 1, 2017, the Company adopted ASU 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, which eliminated the Step 2 requirement of the goodwill impairment test. Instead, the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount. The Company determined that the decrease in its market capitalization in the first quarter of 2017 constituted an indicator of impairment and therefore a goodwill impairment test was completed as of March 31, 2017
CY2018Q4	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1
CY2018Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	38255000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	7143000
CY2018Q4	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	2682000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	28430000
CY2018Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	43077000
CY2018Q4	cdna	Intangible Assets Excluding Goodwill Accumulated Amortization IntangibleAssetsExcludingGoodwillAccumulatedAmortization	7143000
CY2018Q4	cdna	Intangible Assets Excluding Goodwill Foreign Currency Translation Gain Loss IntangibleAssetsExcludingGoodwillForeignCurrencyTranslationGainLoss	-2682000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	37875000
CY2017Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1489000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18234000
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	17559000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14100000
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15484000
CY2018	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Period Increase Decrease AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease	2400000
CY2018	us-gaap	Adjustment For Amortization AdjustmentForAmortization	153047
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4166000
CY2017Q4	cdna	Finite Lived Intangible Foreign Currency Translation FiniteLivedIntangibleForeignCurrencyTranslation	570000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	33139000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2400000
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2600000
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1700000
CY2017Q4	cdna	Indefinite Lived Intangible Assets Excluding Goodwill Gross IndefiniteLivedIntangibleAssetsExcludingGoodwillGross	6700000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	2998000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	2998000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	2794000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	2794000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	2794000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	14052000
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2506000
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2569000
CY2018Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	651000
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1471000
CY2018Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1786000
CY2017	us-gaap	Adjustment For Amortization AdjustmentForAmortization	135000
CY2016	us-gaap	Adjustment For Amortization AdjustmentForAmortization	204000
CY2018Q4	cdna	Accrued Clinical And Cost Of Other Studies Current AccruedClinicalAndCostOfOtherStudiesCurrent	1815000
CY2017Q4	cdna	Accrued Clinical And Cost Of Other Studies Current AccruedClinicalAndCostOfOtherStudiesCurrent	1115000
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	822000
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	475000
CY2018Q4	cdna	Accrued Sample Processing Fees AccruedSampleProcessingFees	657000
CY2017Q4	cdna	Accrued Sample Processing Fees AccruedSampleProcessingFees	633000
CY2018Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	432000
CY2017Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	419000
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	285000
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	0
CY2018Q4	cdna	Customer Overpayments And Refunds Due CustomerOverpaymentsAndRefundsDue	184000
CY2017Q4	cdna	Customer Overpayments And Refunds Due CustomerOverpaymentsAndRefundsDue	270000
CY2018Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	172000
CY2017Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	13000
CY2018Q4	cdna	Accrued Software Implementation Costs AccruedSoftwareImplementationCosts	58000
CY2017Q4	cdna	Accrued Software Implementation Costs AccruedSoftwareImplementationCosts	94000
CY2018Q4	cdna	Accrued Uninvoiced Receipts AccruedUninvoicedReceipts	0
CY2017Q4	cdna	Accrued Uninvoiced Receipts AccruedUninvoicedReceipts	253000
CY2018Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0
CY2017Q4	us-gaap	Interest Payable Current InterestPayableCurrent	81000
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	983000
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	382000
CY2018	cdna	Leases Expiration Period LeasesExpirationPeriod	2020
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	2000000
CY2017	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1700000
CY2016	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1500000
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	193000
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	193000
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	67000
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	0
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	453000
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	32000
CY2018Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	421000
CY2018Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	249000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2161000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2045000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	10000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	7000
CY2018Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	4223000
CY2017	cdna	License And Maintenance Fees LicenseAndMaintenanceFees	100000
CY2018	us-gaap	Payments For Royalties PaymentsForRoyalties	700000
CY2018	cdna	Description Of Agreement Expected Expiration Year DescriptionOfAgreementExpectedExpirationYear	The agreement will expire at the later of the last-to-expire patent in the EEA or ten years from the first commercial sale of the test in the EEA, which occurred in 2014.
CY2013Q2	cdna	Upfront Payment In Cash UpfrontPaymentInCash	387500
CY2013Q2	cdna	Upfront Payment In Cash UpfrontPaymentInCash	408000
CY2013Q2	cdna	Potential Refundable Portion Of Upfront Payment PotentialRefundablePortionOfUpfrontPayment	250000
CY2013Q2	cdna	Potential Refundable Portion Of Upfront Payment PotentialRefundablePortionOfUpfrontPayment	263000
CY2018	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	39000
CY2017	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	39000
CY2016	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	2000
CY2018Q4	cdna	Royalty Revenue Receivable RoyaltyRevenueReceivable	0
CY2017Q4	cdna	Royalty Revenue Receivable RoyaltyRevenueReceivable	0
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4600000
CY2017Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	300000
CY2016Q2	cdna	Common Stock Purchase Price CommonStockPurchasePrice	3.99
CY2016Q2	cdna	Payments For Transfer Agents Legal Fees And Other Direct Issuance Costs PaymentsForTransferAgentsLegalFeesAndOtherDirectIssuanceCosts	1800000
CY2018	cdna	Additional Issued Units AdditionalIssuedUnits	334169
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	300000
CY2016Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	1700000
CY2016Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1002507
CY2017	cdna	Estimated Fair Value Of Warrant Liability Remeasurement Charge EstimatedFairValueOfWarrantLiabilityRemeasurementCharge	11300000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	156429
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1957075
CY2018	cdna	Share Based Compensation Arrangement By Share Based Payment Award Common Stock Awards For Services ShareBasedCompensationArrangementByShareBasedPaymentAwardCommonStockAwardsForServices	25509
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1116683
CY2018	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriod	0
CY2018	cdna	Share Based Compensation Arrangement By Share Based Payment Award Repurchases Of Common Stock Under Employee Incentive Plans ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasesOfCommonStockUnderEmployeeIncentivePlans	67656
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	46490
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	82576
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1878
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	322178
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1941473
CY2018	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Assumed From Acquisitions In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedFromAcquisitionsInPeriod	0
CY2018	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	472645
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2501057
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.21
CY2018	cdna	Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Exercised Price Shares Reserved ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageExercisedPriceSharesReserved	0
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	14.78
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	3.13
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.26
CY2018	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	3.51
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.10
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	6800000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-4000
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-251000
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	4000
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1000
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-49000
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1614000
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1890000
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-1398000
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1597000
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1847000
CY2018Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingNumber	1020905
CY2018Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber	1301026
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2321931
CY2018	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice	5.26
CY2018Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice	11.77
CY2018	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm	P6Y8M19D
CY2018	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingWeightedAverageRemainingContractualTerm	P9Y14D
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
CY2018Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedOutstandingAggregateIntrinsicValue	20299000
CY2018Q4	cdna	Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue	17728000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	38027000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.05
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.60
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.05
CY2018	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1200000
CY2018Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	8700000
CY2018	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y3M
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7138000
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1744000
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1998000
CY2018	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0
CY2018	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	0
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-41109000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-50132000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-21753000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-7106000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-7137000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-19609000
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	24000
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	74000
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	49000
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	11000
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	139000
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	68000
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	32000
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	163000
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	138000
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	92000
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	13000
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	42000
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1698000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.013
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.002
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.005
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.094
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.380
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.168
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.024
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	49374000
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	5252000
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2431000
CY2018	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	285000
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	186000
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	332000
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-21400000
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3164000
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2968000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.011
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.013
CY2018	cdna	Effective Income Tax Rate Reconciliation Warrant Revaluation EffectiveIncomeTaxRateReconciliationWarrantRevaluation	-0.100
CY2017	cdna	Effective Income Tax Rate Reconciliation Warrant Revaluation EffectiveIncomeTaxRateReconciliationWarrantRevaluation	-0.175
CY2016	cdna	Effective Income Tax Rate Reconciliation Warrant Revaluation EffectiveIncomeTaxRateReconciliationWarrantRevaluation	-0.002
CY2018	cdna	Effective Income Tax Rate Reconciliation Interest Expense EffectiveIncomeTaxRateReconciliationInterestExpense	-0.017
CY2017	cdna	Effective Income Tax Rate Reconciliation Interest Expense EffectiveIncomeTaxRateReconciliationInterestExpense	-0.018
CY2016	cdna	Effective Income Tax Rate Reconciliation Interest Expense EffectiveIncomeTaxRateReconciliationInterestExpense	0.000
CY2017	cdna	Effective Income Tax Rate Reconciliation Acquisition Costs EffectiveIncomeTaxRateReconciliationAcquisitionCosts	0.000
CY2016	cdna	Effective Income Tax Rate Reconciliation Acquisition Costs EffectiveIncomeTaxRateReconciliationAcquisitionCosts	-0.012
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.012
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Impairment Losses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses	-0.108
CY2017	cdna	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit Percent TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefitPercent	-0.465
CY2016	cdna	Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit Percent TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefitPercent	0.00
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.006
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.007
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.007
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.030
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.030
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.039
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	52135000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	6235000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	3068000
CY2018Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1571000
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	812000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	63821000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	60327000
CY2018Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3494000
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	6429000
CY2018Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	33000
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6462000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	5798000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	583000
CY2017Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1184000
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	633000
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	57572000
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	54934000
CY2017Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2638000
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	7554000
CY2017Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	17000
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	7571000
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4933000
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	5400000
CY2018	cdna	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	0
CY2017	cdna	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	-2274000
CY2016	cdna	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	2489000
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3449000
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	300000
CY2017Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	300000
CY2016Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	300000
CY2018Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	500000
CY2017Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27983033
CY2018Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40104341
CY2017Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11584000
CY2017	cdna	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Deferred Tax Assets TaxCutsAndJobsActOf2017IncompleteAccountingDeferredTaxAssets	72500000
CY2018	cdna	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Deferred Tax Assets TaxCutsAndJobsActOf2017IncompleteAccountingDeferredTaxAssets	45900000
CY2018Q4	cdna	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Decrease In Valuation Allowance TaxCutsAndJobsActOf2017IncompleteAccountingDecreaseInValuationAllowance	27000000
CY2018Q3	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2018Q3	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2018Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14053000
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	17823000
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	21184000
CY2018Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	23509000
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-8969000
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-14062000
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-19970000
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-3755000
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2018Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2018Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2018Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29615441
CY2018Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	35549837
CY2018Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37154293
CY2018Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40104341
CY2018Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	29615441
CY2018Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	35549837
CY2018Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37154293
CY2017Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12046000
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12191000
CY2017Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	12503000
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-5562000
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-3968000
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-14268000
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-31671000
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.26
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.19
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.63
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.13
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.19
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.63
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.13
CY2017Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21343782
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	21412480
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22526615
CY2017Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27983033
CY2017Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21343782
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	21412480
CY2017Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22526615

Files In Submission

Name	View Source	Status
0001564590-19-006533-index-headers.html	Edgar Link	pending
0001564590-19-006533-index.html	Edgar Link	pending
0001564590-19-006533.txt	Edgar Link	pending
0001564590-19-006533-xbrl.zip	Edgar Link	pending
cdna-10k_20181231.htm	Edgar Link	pending
cdna-20181231.xml	Edgar Link	completed
cdna-20181231.xsd	Edgar Link	pending
cdna-20181231_cal.xml	Edgar Link	unprocessable
cdna-20181231_def.xml	Edgar Link	unprocessable
cdna-20181231_lab.xml	Edgar Link	unprocessable
cdna-20181231_pre.xml	Edgar Link	unprocessable
cdna-ex211_8.htm	Edgar Link	pending
cdna-ex231_729.htm	Edgar Link	pending
cdna-ex232_728.htm	Edgar Link	pending
cdna-ex311_11.htm	Edgar Link	pending
cdna-ex312_6.htm	Edgar Link	pending
cdna-ex321_9.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CDNA
CareDx Inc Stock $cdna

2018 Form 10-K Financial Statement

#000156459019006533 Filed on March 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDNA CareDx Inc Stock $cdna

2018 Form 10-K Financial Statement

#000156459019006533 Filed on March 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CDNA
CareDx Inc Stock $cdna